These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3098121)

  • 21. Effects of alpha-difluoromethylornithine on protein synthesis and synthesis of the variant-specific glycoprotein (VSG) in Trypanosoma brucei brucei.
    Bitonti AJ; Cross-Doersen DE; McCann PP
    Biochem J; 1988 Feb; 250(1):295-8. PubMed ID: 3128277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
    Yun O; Priotto G; Tong J; Flevaud L; Chappuis F
    PLoS Negl Trop Dis; 2010 May; 4(5):e720. PubMed ID: 20520803
    [No Abstract]   [Full Text] [Related]  

  • 23. Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.
    Sarić M; Clarkson AB
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2545-52. PubMed ID: 7872745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphological changes in Trypanosoma brucei rhodesiense following inhibition of polyamine biosynthesis in vivo.
    de Gee AL; Carstens PH; McCann PP; Mansfield JM
    Tissue Cell; 1984; 16(5):731-8. PubMed ID: 6440309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei.
    Bacchi CJ; Garofalo J; Mockenhaupt D; McCann PP; Diekema KA; Pegg AE; Nathan HC; Mullaney EA; Chunosoff L; Sjoerdsma A; Hutner SH
    Mol Biochem Parasitol; 1983 Mar; 7(3):209-25. PubMed ID: 6193423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [African trypanosomiasis in children treated with eflornithine. A case].
    Benhamou PH; Chandenier J; Schechter PJ; Epelbaum S; Tell GP; Haegele KD; Pautard JC; Piussan C
    Presse Med; 1989 Jun; 18(24):1199-202. PubMed ID: 2525760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.
    Van Nieuwenhove S; Schechter PJ; Declercq J; Boné G; Burke J; Sjoerdsma A
    Trans R Soc Trop Med Hyg; 1985; 79(5):692-8. PubMed ID: 3938090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Loko L; Ethier L; Mpia B; Pépin J
    Trans R Soc Trop Med Hyg; 1993; 87(4):473-7. PubMed ID: 8249087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy of trypanosomiasis: the potentiation of antimonial compounds by difluoromethylornithine (DFMO).
    Jennings FW
    Trop Med Parasitol; 1991 Jun; 42(2):135-8. PubMed ID: 1654590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [African sleeping sickness].
    Eyckmans L
    Rev Med Liege; 1988 Jun; 43(11):440-4. PubMed ID: 3135564
    [No Abstract]   [Full Text] [Related]  

  • 31. Pneumocystis carinii polyamine catabolism.
    Merali S
    J Biol Chem; 1999 Jul; 274(30):21017-22. PubMed ID: 10409651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parasite Polyamines as Pharmaceutical Targets.
    Roberts S; Ullman B
    Curr Pharm Des; 2017; 23(23):3325-3341. PubMed ID: 28571553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review.
    Sahai J; Berry AJ
    Pharmacotherapy; 1989; 9(1):29-33. PubMed ID: 2493638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis.
    Heby O; Persson L; Rentala M
    Amino Acids; 2007 Aug; 33(2):359-66. PubMed ID: 17610127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DL-alpha-difluoromethylornithine (DFMO)-Berenil combination: therapeutic and prophylactic activity against Trypanosoma brucei brucei infection in mice.
    Onyeyili PA; Egwu GO; Zaria LT; Orjiude BA
    Rev Elev Med Vet Pays Trop; 1991; 44(4):443-5. PubMed ID: 1843826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular mechanism for eflornithine resistance in African trypanosomes.
    Vincent IM; Creek D; Watson DG; Kamleh MA; Woods DJ; Wong PE; Burchmore RJ; Barrett MP
    PLoS Pathog; 2010 Nov; 6(11):e1001204. PubMed ID: 21124824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
    Clarkson AB; Sarić M; Grady RW
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1833-5. PubMed ID: 2285303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases.
    Pearson RD; Hewlett EL
    Ann Intern Med; 1985 Nov; 103(5):782-6. PubMed ID: 3901852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
    Steverding D; Rushworth SA
    Exp Parasitol; 2017 Jul; 178():45-50. PubMed ID: 28552794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.